Table 4.

The 41 validation set interactions that were used to characterize the DIKB’s prediction performance.

Pair	Source
alprazolam* - erythromycin	[29]
alprazolam* - itraconazole	[30]
alprazolam* - ketoconazole	[31], [32]
alprazolam* - nefazodone	[33], [34]
atorvastatin* - erythromycin	[35]
atorvastatin* - nefazodone	[36]
clarithromycin - atorvastatin*	[37], [38]
clarithromycin* - fluconazole	[39]
clarithromycin - pravastatin*	[38]
diltiazem - beta-OH-lovastatin*	[40]
diltiazem - lovastatin*	[41]
diltiazem - midazolam*	[42]
diltiazem - simvastatin*	[43]
diltiazem - triazolam*	[44]
erythromycin - beta-OH-simvastatin*	[45]
erythromycin - simvastatin*	[45]
fluconazole - 1′-OH-midazolam*†	[46]
fluconazole - fluvastatin*	[47]
itraconazole - atorvastatin*	[48]
itraconazole - beta-OH-lovastatin*	[10]
itraconazole* - erythromycin	[49]
itraconazole - lovastatin*	[10]
itraconazole - ortho-OH-atorvastatin* †	[48]
itraconazole - pravastatin*	[48]
itraconazole - rosuvastatin*	[14]
ketoconazole - simvastatin*	[50]
midazolam* - clarithromycin	[51], [52]
midazolam* - erythromycin	[53]
midazolam* - fluconazole	[46], [54]
midazolam* - itraconazole	[55]
midazolam* - ketoconazole	[55]
midazolam* - nefazodone	[56]
nefazodone - 4-OH-alprazolam* †	[34]
nefazodone - beta-OH-simvastatin*	[36]
nefazodone - simvastatin*	[36]
triazolam* - clarithromycin	[17]
triazolam* - erythromycin	[57]
triazolam* - fluconazole	[58]
triazolam* - itraconazole	[59], [60]
triazolam* - ketoconazole	[60], [61]
triazolam* - nefazodone	[62]

Asterisks indicate the object of a metabolic inhibition interaction occurring between the pair.

^†The noted interaction occurs by inhibition of the metabolic clearance of a parent compound.